On June 5, 2025, Roth Capital took significant steps in extending its analytical coverage to PolyPid (PYPD, Financial), a company recognized for its innovative pharmaceutical solutions. Roth Capital's analyst, Boobalan Pachaiyappan, has announced a "Buy" rating for PYPD, highlighting the potential of this stock in the market.
The announcement includes a price target of USD 9.00 for PYPD, marking the initiation of this coverage. This indicates Roth Capital's positive outlook on PolyPid's market position and future performance.
This development is crucial for investors tracking PolyPid (PYPD, Financial) as it underscores confidence in the company's strategy and anticipated growth trajectory. The absence of a prior adjusted price target further emphasizes the significance of this initiation by Roth Capital.
Investors and analysts alike are paying close attention to PYPD following this rating initiation, as it could signal upward trends and growth opportunities within its sector.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 3 analysts, the average target price for PolyPid Ltd (PYPD, Financial) is $11.33 with a high estimate of $13.00 and a low estimate of $10.00. The average target implies an upside of 253.24% from the current price of $3.21. More detailed estimate data can be found on the PolyPid Ltd (PYPD) Forecast page.
Based on the consensus recommendation from 3 brokerage firms, PolyPid Ltd's (PYPD, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
